Skyrizi (risankizumab ... disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya (tildrakizumab). It can be used to treat adults with moderate to ...

and Tremfya (guselkumab), Eli Lilly's Omvoh (mirikizumab), and Sun Pharma's Ilumya (tildrakizumab). Oral IL-23-directed alternatives are starting to filter through the industry pipeline that aim ...

Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia (PHN) than those receiving ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48.

The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderately to severely active Crohn’s disease (CD). The approval marks ...

Most patients with moderate to severe CD who did not initially respond to risankizumab achieved clinical response after extension. Delayed responders also demonstrated clinical and endoscopic ...

Ulcerative Colitis companies are Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

"I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer's disease." HealthDay News — For individuals with ...

An expert discusses how the study assessed real-world effectiveness of tildrakizumab for moderate to severe plaque psoriasis, crucial for validating clinical trial results. Multisite data enhanced ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD). In GALAXI 2 (N=361) and GALAXI 3 (N=360), ...